Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
View/ Open
Date
2022-07-06Author
Davies, FE
Pawlyn, C
Usmani, SZ
San-Miguel, JF
Einsele, H
Boyle, EM
Corre, J
Auclair, D
Cho, HJ
Lonial, S
Sonneveld, P
Stewart, AK
Bergsagel, PL
Kaiser, MF
Weisel, K
Keats, JJ
Mikhael, JR
Morgan, KE
Ghobrial, IM
Orlowski, RZ
Landgren, CO
Gay, F
Caers, J
Chng, WJ
Chari, A
Walker, BA
Kumar, SK
Costa, LJ
Anderson, KC
Morgan, GJ
Type
Journal Article
Metadata
Show full item recordAbstract
The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Collections
Subject
Humans
Multiple Myeloma
Prognosis
Research team
Myeloma Biol Therap
Myeloma Molecular Therapy
Language
eng
Date accepted
2022-07-01
License start date
2022-07-06
Citation
Blood Cancer Discov, 2022, 3 (4), pp. 273 - 284
Publisher
AMER ASSOC CANCER RESEARCH